Among the 312 HCC patients in our cohort, P53 mutations were identified in 83 cases (26.6%).The training dataset comprised 249 patients (80%; mean age 57 ± 9 years [SD]; 194 males [78%], 55 females [22%]), while the test dataset included 63 patients (20%; mean age 55 ± 10 years [SD]; 46 males [73%], 17 females [27%]). This evidence concerns the gene TP53 and hepatocellular carcinoma.